A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
about
Ribavirin plus interferon versus interferon for chronic hepatitis CViral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patientsTwenty four-week peginterferon plus ribavirin after interferon-β induction for genotype 1b chronic hepatitis C.Safety of interferon beta treatment for chronic HCV hepatitis.Prediction of a sustained viral response in chronic hepatitis C patients who undergo induction therapy with double filtration plasmapheresis plus interferon-β/ribavirin.Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infectionEffect of in vitro interferon-beta administration on hepatitis C virus in peripheral blood mononuclear cells as a predictive marker of clinical response to interferon treatment for chronic hepatitis CIs interferon-beta an alternative treatment for chronic hepatitis C?Usefulness of combined application of double-filtration plasmapheresis and twice-daily injections of interferon-β in hemodialysis patients with hepatitis C virus genotype 1b infection and a high viral load.Polymorphisms of NS5B protein relates to early clearance of hepatitis C virus by interferon plus ribavirin: a pilot study.Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin.Quantitation of hepatitis C virus RNA in peripheral blood mononuclear cells in HCV-monoinfection and HIV/HCV-coinfection.Double-Filtration Plasmapheresis plus Interferon-β for HCV-1b Patients with Non-Sustained Virological Response to Previous Combination Therapy.Hepatitis C virus genotypes and hepatic fibrosis regulate 24-h decline of serum hepatitis C virus RNA during interferon therapy in patients with chronic hepatitis C.Indices of initial hepatitis C virus RNA reduction rate to predict efficacy of interferon-beta followed by peginterferon plus ribavirin for genotype 1b high viral load.Guidelines for the Management of Hepatitis C Virus Infection: First edition, May 2012, The Japan Society of Hepatology.Prediction of sustained response to low-dose pegylated interferon alpha-2b plus ribavirin in patients with genotype 1b and high hepatitis C virus level using viral reduction within 2 weeks after therapy initiation.Potent induction therapy with interferon and ribavirin combination therapy does not achieve a higher sustained virological response rate in chronic hepatitis C with genotype 1b and high hepatitis C virus RNA level.Combination therapy of natural human interferon-beta and ribavirin for chronic hepatitis C patients with injection drug use.Occurrence of clinical depression during combination therapy with pegylated interferon alpha or natural human interferon beta plus ribavirin.Efficacy of the regimen using twice-daily β-interferon followed by the standard of care for chronic hepatitis C genotype 1b with high viral load.
P2860
Q24240879-A09E14F8-DA2C-42C5-817E-DE4273E6CA54Q33675362-9C7E3CF5-4D70-4194-B6EC-5D21729A0BCDQ34390274-2C185878-5B63-4AA0-B39A-1D2CABE93F20Q35616376-922277E2-4A5B-42A5-BD04-3A802CE05CE8Q35754227-DE208C5F-4179-41C7-9C45-1361758DAF39Q35825285-9036C6D7-5A74-4A32-AABC-8C77E7A453AEQ36474178-F033EF5B-DC49-415A-B830-B64BB4C7C596Q36485760-E2FCAA9F-45B0-47F4-BE32-5EB94BA32B71Q42283790-2261B4F0-3F9F-4933-B95A-D10F6F88DD2FQ42984713-0E047129-7D14-4D33-8E21-7BFA556E3771Q42986419-2E32F60C-F549-4724-8E64-6C77176318D7Q43037733-3346C564-45AB-4D4B-BB88-1E4C4666AC0BQ43046596-A0E331AB-4833-4F18-B24E-778304045D7CQ43047749-61A9610F-CCF4-4D7A-BAAE-DCEA984081C5Q43049155-36D24061-64FE-4F4B-ADC1-6AD7544B3A35Q45350857-2ADE5158-EFBF-4B6A-8D66-CDEC4A96D27FQ45353010-993EC54B-1C5A-46E8-985E-C27649EC9F71Q45362984-3818E2DB-A015-4004-BB73-C8E1E62D0684Q45402889-582E668D-7C99-4C3E-B440-88D24A4C1DBEQ46671103-0206E34C-9E8E-467C-93AC-04176C2FDD2CQ48269156-8C3D3DE9-ABDF-4DE9-A55B-4EF672092AFCQ50552508-5425AF36-441B-455E-8D79-546EA001C2DA
P2860
A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
A potent antiviral effect on h ...... reatment with interferon beta.
@en
A potent antiviral effect on h ...... reatment with interferon beta.
@nl
type
label
A potent antiviral effect on h ...... reatment with interferon beta.
@en
A potent antiviral effect on h ...... reatment with interferon beta.
@nl
prefLabel
A potent antiviral effect on h ...... reatment with interferon beta.
@en
A potent antiviral effect on h ...... reatment with interferon beta.
@nl
P2093
P356
P1433
P1476
A potent antiviral effect on h ...... reatment with interferon beta.
@en
P2093
Kanazawa N
Tsuchiya K
Uchihara M
P304
P356
10.1053/JHEP.2001.26086
P407
P577
2001-08-01T00:00:00Z